Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis

by Benjamin Miao PharmD, Bhavana Chalupadi PharmD, Brendan Clark PharmD, Alexis Descoteaux PharmD, Daniel Huang PharmD, Sabrina Ilham PharmD, Brian Ly PharmD, Alex C. Spyropoulos MD, Craig I. Coleman PharmD
Published 2019-05-01

Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study

by Alex C. Spyropoulos MD, Dimitrios Giannis MD, MSc, Jessica Cohen MD, Suja John DNP, Anne Myrka BS(Pharm)MAT, Damian Inlall BS, MBA, CCRC, Michael Qiu MD, PhD, Saydi Akgul BS, MPH, Roger J. Hyman BSc(c), Jason J. Wang PhD
Published 2020-06-01

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study

by Alex C. Spyropoulos MD, Concetta Lipardi MD, PhD, Jianfeng Xu PhD, Wentao Lu PhD, Eunyoung Suh PhD, Zhong Yuan MD, PhD, Bennett Levitan MD, PhD, Chiara Sugarmann BSN, MSHS, Yoriko De Sanctis MS, Theodore E. Spiro MD, Elliot S. Barnathan MD, Gary E. Raskob PhD
Published 2019-11-01